Patidegib

DRUG2 trials

Sponsors

PellePharm, Inc.

Conditions

Basal Cell CarcinomasBasal Cell Nevus Syndrome

Phase 2

Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients

CompletedNCT02762084

PellePharm, Inc.Basal Cell Nevus Syndrome

Start: 2016-06-06End: 2017-04-24Updated: 2020-07-23

Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas

CompletedNCT02828111

PellePharm, Inc.Basal Cell Carcinomas

Start: 2016-11-11End: 2017-11-09Updated: 2019-01-08

Related Papers

Hedgehog pathway inhibition by topical patidegib to reduce BCC burden in patients with basal cell nevus (Gorlin) syndrome.

Journal of Clinical Oncology2018-05-2030 citations